- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05152628
A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients
April 1, 2024 updated by: Astellas Pharma China, Inc.
A Multicenter, Open-label, Non-comparative Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients
The purpose of this study is to determine the pharmacokinetics of tacrolimus following oral administration of Modigraf, after the first oral dose and at steady state in pediatric participants undergoing de novo allograft liver or kidney transplantation.
This study will also observe the safety and efficacy of Modigraf in de novo pediatric allograft liver and kidney transplantation recipients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Pediatric participants will be treated with a Modigraf (tacrolimus granules) based immunosuppressive regimen for 12 months.
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Astellas Pharma China, Inc.
- Phone Number: +86-010-85216332/3
- Email: astellas.registration@astellas.com
Study Locations
-
-
-
Beijing, China
- Site CN86003
-
Guangzhou, China
- Site CN86002
-
Shanghai, China
- Site CN86001
-
Wuhan, China
- Site CN86004
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participant's parent(s) or their legal representative(s), and participant where applicable agrees not to participate in another interventional study while participating in the present study from 1 month before screening to the end of the study.
Exclusion Criteria:
- Participant has previously received another organ transplant.
- Participant has a high immunological risk, defined as a panel reactive antibody (PRA) score > 50% in the previous 6 months (only applicable for kidney transplantation recipients).
- Cold ischemia time of the donor kidney longer than 30 hours (only applicable for kidney transplantation recipients).
- Bilateral kidney transplantation recipients (only applicable for kidney transplantation recipients).
- Participant receives an ABO incompatible donor organ.
- Participant has significant kidney impairment, defined as having serum creatinine ≥ 230 μmol/L (≥ 2.6 mg/dL) prior to transplantation (not applicable for kidney transplantation recipients).
- Participant has significant liver disease, defined as having elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin (TBL) levels 3 times the upper value of the normal range prior to transplantation (not applicable for liver transplantation recipients).
- Participants with malignancies or a history of malignancy within the last 5 years.
- Participant has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer.
- Recipient or donor known to be human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) positive.
- Participant requires systemic immunosuppressive medication for any indication other than transplantation.
- Participants taking or requiring to be treated with medication or substances prohibited by this protocol.
- Known allergy or intolerance to steroids, macrolide antibiotics, basiliximab, or tacrolimus.
- Participants with severe primary disease/complications/poor general condition which may be unsuitable for participating in this study.
- Participant is currently participating in another clinical trial and/or has been taking any other study drug within 1 month prior to screening.
- Participant is unlikely to comply with the visits scheduled in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tacrolimus granules (Modigraf)
Participants will receive the first dose of Modigraf in the morning within 24 hours after reperfusion.
Total initial dose will be received in two divided doses post operatively.
Subsequent oral Modigraf doses will be adjusted by the investigator and will be received in two doses (recommended interval 12 hours)
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of tacrolimus in whole blood: area under the blood concentration - time curve for a dosing interval (AUCtau)
Time Frame: Up to 14 days
|
AUCtau will be recorded from the pharmacokinetic (PK) whole blood sample collected.
|
Up to 14 days
|
Pharmacokinetics of tacrolimus in whole blood: maximum concentration (Cmax)
Time Frame: Up to 14 days
|
Cmax will be recorded from the PK whole blood sample collected.
|
Up to 14 days
|
Pharmacokinetics of tacrolimus in whole blood: time to attain Cmax (tmax)
Time Frame: Up to 14 days
|
tmax will be recorded from the PK whole blood sample collected.
|
Up to 14 days
|
Pharmacokinetics of tacrolimus in whole blood: blood concenration at the end of a dosing interval (Ctrough)
Time Frame: Up to 14 days
|
Ctrough will be recorded from the PK whole blood sample collected.
|
Up to 14 days
|
Determine the correlation between Ctrough and AUCtau PK parameters
Time Frame: up to 14 days
|
The correlation between Ctrough and AUCtau PK parameters will be assessed by Pearson's coefficient at each sample time.
|
up to 14 days
|
Incidence of rejection episodes
Time Frame: Up to 12 months
|
The reporting of acute rejection includes any biopsy-proven or clinically suspected rejection of a participant after transplantation.
|
Up to 12 months
|
Number of participant survivals
Time Frame: Up to 12 months
|
Participant survival status will be recorded during 12 months post-transplant.
|
Up to 12 months
|
Number of graft survivals
Time Frame: Up to 12 months
|
Graft failure is defined as graft dysfunction, including re-transplantation or death.
|
Up to 12 months
|
Number of dose changes throughout the study period
Time Frame: Up to 12 months
|
The number of dose changes will be recorded throughout the study period.
|
Up to 12 months
|
Number of participants with Adverse Events (AEs)
Time Frame: Up to 12 months
|
An AE is defined as any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have a causal relationship with this treatment.
An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not related to study drug.
|
Up to 12 months
|
Number of participants with laboratory value abnormalities and/or adverse events (AEs)
Time Frame: Up to 12 months
|
Number of participants with potentially clinically significant laboratory values.
|
Up to 12 months
|
Number of participants with vital sign abnormalities and/or adverse events (AEs)
Time Frame: Up to 12 months
|
Number of participants with potentially clinically significant vital sign values.
|
Up to 12 months
|
Number of participants with electrocardiogram (ECG) abnormalities and/or adverse events (AE)
Time Frame: Up to 12 months
|
Number of participants with potentially clinically significant ECG values.
|
Up to 12 months
|
Assess levels of Tacrolimus whole blood trough using a local assay method
Time Frame: Up to 12 months
|
Tacrolimus whole blood trough levels will be routinely monitored using a local assay method, for example EMITÒ or Liquid-Chromatography-Mass-Spectrometry-Mass-Spectrometry (LC-MS-MS) in local laboratories.
|
Up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Manager Medical Science, Astellas Pharma China, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2022
Primary Completion (Actual)
March 6, 2024
Study Completion (Actual)
March 6, 2024
Study Registration Dates
First Submitted
November 29, 2021
First Submitted That Met QC Criteria
November 29, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F506-CL-0405
- CTR20212678 (Registry Identifier: ChinaDrugTrials.org.cn)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development.
Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared.
Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD Sharing Time Frame
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD Sharing Access Criteria
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data.
The research proposal is reviewed by an Independent Research Panel.
If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
NovartisCompletedLiver Transplantation | Kidney TransplantationSwitzerland
-
University of Wisconsin, MadisonTerminatedLiver Transplantation | Kidney TransplantationUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
Clinical Trials on Tacrolimus granules
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Bing ShuHuadong Hospital; Longhua Hospital; The First Affiliated Hospital of Anhui University...WithdrawnRenal Insufficiency, Chronic | Renal OsteodystrophyChina
-
Shanghai Jiao Tong University School of MedicineShijiazhuang Yiling Pharmaceutical Co. LtdUnknown
-
Tasly Pharmaceutical Group Co., LtdNot yet recruiting
-
Smilebiotek Zhuhai LimitedRecruitingIntermediate Age-Related Macular DegenerationChina
-
Peking Union Medical College HospitalActive, not recruiting
-
Children's Hospital of Fudan UniversityCompletedPrecocious PubertyChina
-
Chinese University of Hong KongRecruiting